Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer. J Surg Oncol 2016 Sep;114(3):291-5

Date

06/07/2016

Pubmed ID

27264017

DOI

10.1002/jso.24316

Scopus ID

2-s2.0-84983364793 (requires institutional sign-in at Scopus site)   19 Citations

Abstract

Treatment sequencing for resectable pancreatic cancer remains controversial and there is lack of level one evidence comparing neoadjuvant versus adjuvant strategies. However, a comparison of the cost-effectiveness analysis of the treatment strategies may help to better define the healthcare value of each approach. This review will highlight the rationale for multimodality therapy in the treatment of pancreatic cancer, discuss the advantages and disadvantages of adjuvant therapy, and conceptualize the cost-effectiveness of a neoadjuvant approach with regard to healthcare value. J. Surg. Oncol. 2016;114:291-295. © 2016 Wiley Periodicals, Inc.

Author List

Asare EA, Evans DB, Erickson BA, Aburajab M, Tolat P, Tsai S

Authors

Beth A. Erickson MD Professor in the Radiation Oncology department at Medical College of Wisconsin
Douglas B. Evans MD Professor in the Surgery department at Medical College of Wisconsin
Parag P. Tolat MD Chief, Professor in the Radiology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Antineoplastic Agents
Cost-Benefit Analysis
Humans
Neoadjuvant Therapy
Pancreatectomy
Pancreatic Neoplasms